• search

Saridon among 327 combination drugs banned

Subscribe to Oneindia News
For Quick Alerts
ALLOW NOTIFICATIONS
For Daily Alerts

    New Delhi, Sep 13: The Union Health Ministry has banned the sale and distribution of 328 fixed dose combination of drugs. The bans came into effect immediately. Six other drugs have been restricted.

    Saridon among 327 combination drugs banned

    Among those drugs to be affected are painkiller Saridon, combination diabetes drug Gluconorm, antibiotic Lupidiclox and Taxim AZ which is an antibacterial cream.

    Also Read | Chemists strike on September 28

    The government had banned 344 FDCs on March 10 2016, but the same was contested by the manufacturers. On December 15 2017, the Supreme Court had asked for the matter to be examined by the Drug Technical Advisory Board.

    The board concluded in its report that there was no therapeutic justification for the ingredients in the FDCs and these could be a risk to the people. The board went on to recommend a ban.

    Also Read | Access to essential medicines a problem in India, says a study

    In the case of the six other FDCs, the board recommended restricted manufacture and sale subject to certain conditions. The SC on the other hand ruled that the government could not use the board to prohibit 15 of the 344 drugs in the original list as they have been manufactured in India since before 1988. Due to this several popular syrups, painkillers and cold medication with sales amounting to over Rs 740 annually were exempted. The court however told the ministry it could still look into the safety of these 15 drugs by initiating fresh investigation, if it wanted to ban them.

    Drugs that have been banned

    • Saridon
    • Pandem
    • Gluconorm PG
    • Taxim AZ

    Drugs that escaped the ban:

    • Phensedyl Cough Linctus
    • D-Cold Total
    • Corex

    For Breaking News from Oneindia
    Get instant news updates throughout the day.

    X
    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more